Once radiographic progression of disease (PD) is confirmed, the subject and site staff will be unblinded to treatment assignment. Subjects who are determined to be receiving placebo upon unblinding after centrally confirmed radiographic PD, and who are not in need of immediate chemotherapy or radiotherapy, will have the option to cross over to receive vorasidenib, provided certain eligibility criteria are met.
To find current study sites and to learn how to enroll your patient, please see the INDIGO Study Site Locator.
The effectiveness and safety of vorasidenib have not been established. There is no guarantee that vorasidenib will receive health authority approval or become commercially available in any country for the use being investigated.
Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 Mutations in Gliomas. N Engl J Med. 2009; 360(8):765-773.
Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015; 372(26):2481-2498.
NCT02481154, Mellinghoff et al. Society of Neuro-oncology Annual Meeting 2018.
NCT03343197, Mellinghoff et al. American Society of Clinical Oncology Annual Meeting 2019.
You are about to leave this website and enter a website operated by an independent third party.
By clicking on a link, you may enter a different part of this website, or a website outside of www.indigostudy.com. Websites administered by third parties are governed by their own Legal and Privacy Policies. Servier assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third-party sites. Additionally, the presence of this link does not imply the third-party site’s endorsement of Servier or this website.
We automatically collect information about you using cookies, web beacons, and similar technologies. We use these tools to analyze how our products perform and improve our services.